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Background: Rheumatoid arthritis and osteoarthritis are two common musculoskeletal disorders that affect the
joints. Despite high prevalence rates, etiological factors involved in these disorders remain largely unknown.
Dissecting the molecular aspects of these disorders will significantly contribute to improving their diagnosis and
clinical management. In order to identify proteins that are differentially expressed between these two conditions, a
quantitative proteomic profiling of synovial fluid obtained from rheumatoid arthritis and osteoarthritis patients was
carried out by using iTRAQ labeling followed by high resolution mass spectrometry analysis.
Results: We have identified 575 proteins out of which 135 proteins were found to be differentially expressed by
≥3-fold in the synovial fluid of rheumatoid arthritis and osteoarthritis patients. Proteins not previously reported to
be associated with rheumatoid arthritis including, coronin-1A (CORO1A), fibrinogen like-2 (FGL2), and macrophage
capping protein (CAPG) were found to be upregulated in rheumatoid arthritis. Proteins such as CD5 molecule-like
protein (CD5L), soluble scavenger receptor cysteine-rich domain-containing protein (SSC5D), and TTK protein kinase
(TTK) were found to be upregulated in the synovial fluid of osteoarthritis patients. We confirmed the upregulation
of CAPG in rheumatoid arthritis synovial fluid by multiple reaction monitoring assay as well as by Western blot.
Pathway analysis of differentially expressed proteins revealed a significant enrichment of genes involved in
glycolytic pathway in rheumatoid arthritis.
Conclusions: We report here the largest identification of proteins from the synovial fluid of rheumatoid arthritis
and osteoarthritis patients using a quantitative proteomics approach. The novel proteins identified from our study
needs to be explored further for their role in the disease pathogenesis of rheumatoid arthritis and osteoarthritis.
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Rheumatoid arthritis (RA) is a common systemic auto-
immune disorder. Around 0.5-1% of the adult popula-
tion is affected with RA in the developed countries with
5–50 per 100,000 new cases reported annually [1]. RA is
characterised by persistent inflammation of the synovial
membrane and pannus formation that results in joint
damage and loss of function [1,2]. Genetic, environmen-
tal and stochastic factors act together to contribute to
the pathogenesis of RA [3]. Osteoarthritis (OA) is a pro-
gressive disorder characterized by the degradation of the
cartilage, osteophyte formation, mild to moderate syn-
ovial inflammation, narrowing of the joint space and
subchondral sclerosis [4,5]. It is one of the most preva-
lent musculoskeletal diseases that lead to disability in
~40% of the adults over 70 years [5].
Despite significant advances towards the understand-
ing of the pathophysiology of RA and OA, early diagno-
sis and therapeutic intervention remain a challenge [6].
RA is usually diagnosed based on clinical symptoms and
the presence of antibodies against rheumatoid factor
(RF) and cyclic citrullinated peptides (CCPs) in serum
[7]. Although RF has been traditionally used as a bio-
marker for RA, it lacks specificity as it is also detected
in the sera of several other autoimmune disorders and
infectious diseases as well as in the healthy elderly popu-
lation (10-30%) [7,8]. Antibodies to CCPs have been
shown to be involved in the development of auto-
immune arthritis [9]. Their specificity for RA has been
reported to be higher than RF. However the diagnostic
sensitivity of antibodies to CCPs has been estimated to
be slightly lower than that of RF [10]. In addition to
anti-CCPs, anti-filaggrin (AFA) and anti-Sa antibodies
have also been demonstrated to have high specificity for
RA but with a sensitivity of less than 50% [11]. Assess-
ment of the pathological changes in the OA joint is
mainly carried out using radiography, which is the gold
standard for diagnostic purposes [12]. However, it has
poor sensitivity as the radiographic evidence is obtained
only when the articular cartilage has degraded signifi-
cantly. Thus, this does not provide an account of the ex-
tent of disease progression [12]. Biomarkers that are
useful for early diagnosis or for predicting the outcome/
progression of OA are not currently available [13]. Thus,
there is a need for continued discovery efforts to identify
novel biomarkers with the desired sensitivity and specifi-
city for RA and OA.
Mass spectrometry-based approaches have provided
an impetus for biomarker discovery for a wide range of
diseases. Studying the synovial fluid proteome is benefi-
cial in arthritis as it is in proximity to the site of disease
activity as well as it provides a snapshot of the most
relevant compartment throughout disease progression.
Additionally, alterations in the joint cavity due to injuryor disease may be directly reflected in the composition
of synovial fluid and could be correlated to disease se-
verity and progression [14]. In a previous proteomic
study, surface enhanced laser desorption ionization
(SELDI) mass spectrometry was used to identify proteins
that were present in RA synovial fluid but not in OA
[15]. Subsequently, in another proteomic study, 2-D gel
electrophoresis followed by MALDI-TOF analysis was
carried out to identify synovial fluid and plasma proteins
that could differentiate between RA and reactive arthritis
(ReA) or OA. S100A9, S100A12 and serum amyloid A
(SAA) were found to be present only in RA but not in
ReA and OA in that study [16]. A label free quantitative
analysis of RA and OA synovial fluid proteome by
Mateos et al., resulted in the identification of 135 pro-
teins using MALDI-TOF/TOF mass spectrometer [17].
Proteins involved in complement activation, inflamma-
tion and immune response were found to be relatively
more abundant in RA and those that participated in the
extracellular matrix formation and remodeling were
more abundant in OA synovial fluid [17]. An immuno-
proteomics study has also been reported to identify
autoantigens in RA. In this study, the expression of
vimentin, gelsolin, alpha-2-HS-glycoprotein, glial fibril-
lary acidic protein and alpha-1-B glycoprotein was found
to be reported to be higher in RA synovial fluid than
that of OA [18]. Most of the studies carried out thus far
have adopted a label free quantitation approach and
employed low resolution mass spectrometers to identify
the proteins differentially expressed between RA and
OA.
Isobaric Tags for Relative and Absolute Quantification
(iTRAQ) is a chemical labeling method which uses iso-
baric tags with reporter ion group that react with the
primary amine groups present in the peptides [19].
iTRAQ-based quantitative proteomics approach coupled
to mass spectrometry has been widely used to identify
biomarkers for several diseases including cancer [20–24],
meningitis [25] and rabies [26]. Here, we describe an
iTRAQ-based strategy to relatively quantitate the syn-
ovial fluid proteins from RA and OA. We employed an
iTRAQ-based labeling strategy coupled with LTQ-
Orbitrap Velos mass spectrometer to identify proteins
differentially expressed between RA and OA. The differ-
entially expressed proteins obtained from the study
might increase our knowledge pertaining to the mech-
anism of pathogenesis of RA and OA.
Results and discussion
We employed a quantitative proteomics approach using
iTRAQ labeling to identify the differentially expressed
proteins in RA compared to OA. A schematic workflow
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Figure 1 A schematic workflow illustrating the steps involved
in the differential analysis of RA and OA synovial fluid
proteome. Proteins from RA and OA synovial fluid were extracted
and depleted to remove the 14 most abundant proteins using
multiple affinity removal system, Human-14. The depleted protein
from RA and OA were then digested with trypsin and labeled with
iTRAQ reagents, 117 and 116 respectively. The labeled samples were
pooled and subjected to fractionation using strong cation exchange
chromatography. The fractions were then analyzed on a LTQ-Orbitrap
Velos mass spectrometer. The MS/MS data obtained was searched
against Human RefSeq 50 database using Sequest and Mascot search
algorithms. Validation of the iTRAQ quantitation data was carried out
using multiple reaction monitoring and Western blot.
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A total of 30,226 MS/MS spectra acquired from the LC-
MS/MS analysis of 20 SCX fractions resulted in the iden-
tification of 3,488 unique peptides corresponding to 575
proteins. Out of these 575 proteins, 135 were differentially
expressed between RA and OA by ≥3-fold. A complete list
of all the identified peptides along with their correspond-
ing proteins is provided in Additional file 1: Table S1.Bioinformatics analysis
Subcellular localization and biological process based
classification for the differentially expressed proteins was
performed using HPRD [27,28] (http://www.hprd.org)
that contains information on human proteins manually
curated from the published literature. Signal peptide and
domain analysis was also carried out using the data from
HPRD. Classification based on the subcellular localization
(Figure. 2A) revealed that 34% of the identified proteins
were extracellular. Biological process-based (Figure. 2B)
categorization showed that a majority of the proteins were
involved in cell growth and/or maintenance (22%) and cell
communication or signal transduction (18%). Out of 575
identified proteins, 273 possess a signal peptide, 24 have a
transmembrane domain and 73 have both a signal peptide
and a transmembrane domain.
Differentially expressed proteins between RA and OA
Out of the 135 differentially expressed proteins, 92 were
found to be upregulated and 43 were downregulated in
RA synovial fluid ≥3-fold when compared to OA. Several
proteins that were earlier reported to be associated with
RA and OA were identified in this study confirming the
validity of our approach.
Proteins previously reported to be associated with RA
and OA
S100 family of calcium binding proteins, S100A8, S100A9
and S100A12, have been shown to act as proinflammatory
mediators in various autoimmune disorders including
arthritis [29]. Baillet et al. have shown in a proteomic
study that these S100 proteins were present at higher con-
centration in RA synovial fluid than OA synovial fluid and
could serve as markers to discriminate between RA and
other inflammatory arthritis [30]. In this study, S100A8,
S100A9 and S100A12, were upregulated in the synovial
fluid of RA patients by 9.1-fold, 29-fold and 33.4-fold,
respectively.
Matrix metalloproteinases (MMPs) are zinc dependent
extracellular proteolytic enzymes known to play a major
role in tissue remodelling under both physiological and
pathological conditions [31]. We identified two MMPs,
MMP8 and MMP9, to be more abundant in RA synovial
fluid (14.4-fold and 3.4-fold, respectively). The levels of
these enzymes have already been shown to be elevated
in both synovial fluid and sera of RA patients when com-
pared to OA [32]. We also identified a neutrophil elastase
inhibitor, serpin peptidase inhibitor, clade B member 1
(SERPINB1) that was upregulated (4.1-fold) in RA synovial
fluid. Serpinb1 knock-out mice have been used as a model
to study the role of neutrophil elastase in cellular homeo-
stasis and inflammation [33]. In a comparative proteomic
study between RA and OA, SERPINB1 was detected in
RA synovial fluid but not in OA synovial fluid [17].
A   Subcellular localization
B   Biological process
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Figure 2 Gene Ontology-based classification of differentially expressed proteins identified from RA and OA synovial fluid. (A) Subcellular
localization (B) Biological processes.
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that belongs to the family of high temperature require-
ment family of proteases [34]. Its expression was found
to be higher in the articular cartilage vesicles and tissues
of OA patients than normal controls [35,36]. It has been
shown to be associated with the progression of the ar-
ticular cartilage degeneration and in the regulation of
osteoblast gene expression through the degradation of
extracellular matrix proteins including, fibronectin, dec-
orin and matrix Gla [37,38]. Their levels in the synovial
fluid of OA patients were found to be significantly ele-
vated than RA and non-arthritic subjects [39]. In our
study, it was upregulated in OA synovial fluid by 3.3-
fold. Another serine protease identified in this study is
the fibroblast activation protein (FAP). FAP has been
shown to be expressed by synovial fibroblasts in both
RA and OA patients [40]. Its expression has also been
demonstrated in several bone tumors including low-
grade myofibroblastic sarcoma and osteosarcomas [41].
In this study, it was found to be upregulated in OA syn-
ovial fluid by 5-fold.
Myeloperoxidase (MPO), an oxidoreductase enzyme
was upregulated by 15.6-fold in RA in the current study.
Studies have showed that MPO is highly associated withoxidative stress in the inflamed RA joints. It is present at
higher levels in synovial fluid and plasma of RA patients
[42]. Lipocalin 2 (LCN2), also known as neutrophil asso-
ciated gelatinase lipocalin, is expressed in neutrophils
Lipocalin 2 has been shown to activate MMP9 and pre-
vent the degradation of MMP9 as well [43,44]. When
compared to OA synovial fluid its concentration has
been shown to be significantly higher in RA [17,45]. In
our study, it was upregulated by 7.4- fold in RA when
compared to OA.
Dysregulation of complement proteins is known to
contribute to the pathogenesis of OA [46]. In this study,
we identified several complement components including
complement 4A (C4A), complement component 4 bind-
ing protein, alpha (C4BPA) and complement factor I
(CFI) to be present at higher levels in OA synovial fluid
than RA by 3.3-fold, 5-fold and 3.3-fold, respectively. Re-
cent proteomic studies have demonstrated an aberrant
expression of C4A, C4BPA and CFI in OA synovial fluid
than synovial fluid from healthy individuals, suggesting
their involvement in joint damage [46,47]. Cartilage
intermediate layer protein (CILP) is an extracellular
matrix protein predominantly expressed by the human
articular cartilage [48]. CILP has been shown to be
Balakrishnan et al. Clinical Proteomics 2014, 11:1 Page 5 of 14
http://www.clinicalproteomicsjournal.com/content/11/1/1associated with the progression of OA [49]. It acts as an
autoantigen and contributes to the development of
chronic synovitis in OA [50]. Its presence in the healthy
and OA synovial fluid has been already demonstrated in
a proteomic study [51]. It has been found to be upregu-
lated by 3.3-fold in OA synovial fluid in our study.
Proteins not previously reported to be associated with RA
and OA
We identified several differentially expressed proteins
which have not been previously associated to the patho-
genesis of RA and OA. A partial list of novel proteins up-
regulated in RA and OA is provided in Table 1 and Table 2
respectively. The representative MS/MS spectra for the
novel proteins identified in RA and OA are provided in
Figure 3.
Coronin, actin binding protein 1A (CORO1A) is a mem-
ber of WD repeat protein superfamily expressed in human
neutrophils [52]. It has been shown to be distributed at
the nascent phagosome and at the leading edge of migrat-
ing neutrophils. Functional studies have revealed their role
in chemotaxis and phagocytosis in human neutrophils
[52]. Studies in mice have demonstrated the importance of
CORO1A in T cell survival, by stimulating the release of
Ca2+ from the intracellular reserves upon the activation of
T cell receptor [53]. In Th17 CD4 (+) T cells, CORO1A
served as a positive regulator of TGFβ receptor signaling,
thus enhancing the effector functions of these cells [54].
This protein was upregulated by 6-fold in RA when com-
pared to OA in the present study.
Fibroleukin (FGL2) is a serine protease secreted by T
lymphocytes [55]. The membrane associated fibroleukin
(mFGL2) has prothrombinase activity, whereas the se-
creted form of fibroleukin has an immunosuppressive
effect on T cell proliferation and dendritic cell matur-
ation [56,57]. Studies have shown that Fgl2 is required
for the regulatory activity of T cells and inhibited the de-
velopment of autoimmune glomerulonephritis [58]. A




1 ARPC1B Actin related protein 2/3 complex, subunit 1B, 41 kDa C
2 CORO1A Coronin, actin binding protein, 1A C
3 YWHAE Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, epsilon polypeptide
R
sc
4 CTSZ Cathepsin Z C
5 CAPG Capping protein (actin filament), gelsolin-like C
6 FGL2 Fibrinogen-like 2 E
c
7 TYMP Thymidine phosphorylase Gassociated fibroleukin is highly expressed in the arthritic
joint space of mice with collagen-induced arthritis
(CIA) and its prothrombinase activity contributed to the
deposition of fibrin and subsequent inflammation in
CIA mice [59]. FGL2 was upregulated in RA patients
compared to OA by 3.5-fold.
Different forms of 14-3-3 proteins including 14-3-3 zeta
(YWHAZ), 14-3-3 eta (YWHAH), 14-3-3 theta (YWHAQ)
and 14-3-3 gamma (YWHAG) were identified in our
study. They were upregulated by 9.8-fold, 4.7-fold, 3.2-
fold and 3.1-fold, respectively. 14-3-3 proteins are acidic
dimeric proteins ubiquitously expressed in eukaryotic
cells. These proteins act as phosphoserine/phosphothreo-
nine binding modules. They play significant role in the
prevention of apoptosis, initiation and maintenance of
DNA damage check points, synchronization of cell ad-
hesion and motility [60].
We identified several proteins upregulated in OA that
have not been previously described in the context of
OA. CD5 molecule-like protein (CD5L), also known as
apoptosis inhibitor expressed by macrophages, is an al-
ternative cell surface ligand for CD5, a glycoprotein
expressed on T lymphocytes [61]. It is a soluble protein
that belongs to group B scavenger receptor cysteine-rich
(SRCR) superfamily [62]. Its expression was detected in
the macrophages present in several lymphoid tissues
[63]. It was shown to bind to different types of immune
cells, suggesting its regulatory role in the immune sys-
tem [61]. Biochemical studies of this molecule revealed
that it is an abundant serum protein and might play a
role in the homeostasis of IgM antibodies [62]. CD5L
has been demonstrated to support the survival of macro-
phages and enhanced the phagocytic function of macro-
phages in Corynebacterium parvum induced hepatitis
[64]. In mice, it was also shown to inhibit the apoptosis of
NKT cells and T cells in C. parvum induced granuloma-
tous inflammation [65]. This molecule was upregulated in
OA by 3.3-fold.
Another newly characterized member of the SRCR
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Table 2 A partial list of novel proteins upregulated in OA
Gene symbol Protein Molecular function Cellular component Fold change
(OA/RA)
1 CRISP3 Cysteine-rich secretory protein 3 Extracellular matrix structural constituent Secretory granule 5.0
2 TTK TTK protein kinase Protein threonine/tyrosine kinase activity Centrosome 5.0
3 NOTCH4 Notch 4 Receptor activity Plasma membrane 5.0
4 CD5L CD5 molecule-like Defense/immunity protein activity Extracellular 3.3
5 COL15A1 Collagen, type XV, alpha 1 Extracellular matrix structural constituent Extracellular 3.3
6 SSC5D Scavenger receptor cysteine rich
domain containing (5 domains)
Molecular function unknown - 3.3
7 RTN4RL2 Reticulon 4 receptor-like 2 Receptor activity Plasma membrane 3.3
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by 3.3-fold in RA in our study. Its expression was primar-
ily detected in monocytes/macrophages, T lymphocytes
and placenta [66]. Murine Ssc5d has been shown to bind
to extracellular matrix constituents such as galectin-1 and
laminin as well as to the pathogen-associated molecular
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Figure 3 Representative MS/MS spectra of peptides from novel prote
upregulated in RA: (A) Tyrosine 3-monooxygenase/tryptophan 5-monooxyg
(B) Fibrinogen-like protein 2 (FGL2) (3.5-fold). Novel proteins upregulated in
scavenger receptor cysteine-rich domain-containing protein (SSC5D) (3.3-foinnate defense and homeostasis of the epithelial surfaces
in the host [67].
TTK protein kinase (TTK) is a dual specificity protein
kinase essential for centrosome duplication and mitotic
progression [68]. Its expression has been shown to be in-
creased by TNF-alpha and IL-2 in human chondrocytes
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OA: (C) CD5 antigen-like precursor (CD5L) (3.3-fold), (D) Soluble
ld).
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we have also found proteins including, THAP domain-
containing protein 4, (THAP4) reticulon 4 receptor-like 2
(RTN4RL2) and leucine rich repeat protein 1 (LRR1) to be
upregulated by more than 3-fold in OA.
Although the above-mentioned proteins have been ob-
served to be differentially expressed in the synovial fluid
of RA and OA patients, it is possible that they are not
really associated with the disease but rather contributed
by either individual variation or disease conditions other
than arthritis in these patients. This is why, it is neces-
sary to perform validation studies in a larger cohort of
samples. In addition, it will be useful to determine if
these proteins are detected in synovial or cartilage tis-
sues to understand their association with RA and OA
more fully.
Validation of CAPG by multiple reaction monitoring
(MRM) and Western blot
We adopted a complementary mass spectrometry-based
approach, MRM, as well as Western blotting to validate
the differential expression of macrophage capping pro-
tein, CAPG in RA and OA synovial fluid. CAPG was
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Figure 4 Validation of CAPG by MRM assay and Western blot. A) Box
compared to OA synovial fluid. B) MRM peak traces of the peptide, QAALQ
C) Western blot analysis of CAPG overexpression in RA synovial fluid (n = 1
OA = 10; R-RA, O-OA).by iTRAQ quantitation in our discovery study. This pro-
tein belongs to the gelsolin family and its interaction
with actin is regulated by calcium ions and phosphoino-
sitides [71]. A recent study has speculated its role in me-
diating a cross-talk between actin cytoskeleton and
microtubule-based organelles during cell division [72].
Its association with arthritis has not been reported earl-
ier. CAPG differential expression was confirmed by
MRM in RA and OA synovial fluid including the sam-
ples that were used for iTRAQ quantitation experiment
(Figure 4A and 4B). Western blot analysis also revealed
that CAPG was relatively more abundant in individual
as well as pooled RA synovial fluid samples (n = 10)
when compared to OA synovial fluid samples (n = 10)
(Figure 4C). Both MRM and Western blot data were
consistent with the LC-MS/MS results.
Pathway analysis
Proteins differentially expressed between RA and OA
were subjected to pathway analysis using GeneSpring
software suite in order to identify the functional path-
ways enriched in both the disease conditions. Glycolytic
pathway among other pathways showed significant en-
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and whisker’s plot shows the relative abundance of CAPG in RA
VAEGFISR (z = +2, m/z = 695.38) from CAPG (RT: Retention time).
0) when compared to OA synovial fluid (n = 10) (Pooled: RA = 10 and
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OA. The list of proteins involved in the glycolytic path-
way that were upregulated ≥3-fold in RA is provided in
Table 3. Figure 5 depicts the glycolytic pathway and
highlights the proteins upregulated in RA.
Glycolysis is a primary glucose metabolic pathway that
provides energy for physical activity and coordinates a
variety of physiological processes through complex net-
work of signaling pathways [2]. There have been inde-
pendent reports in the past showing association of
different enzymes involved in glycolytic pathway to RA.
It has been shown that the activities of two key enzymes
of glycolytic pathway, glyceraldehyde 3-phosphate de-
hydrogenase and lactate dehydrogenase, were higher in
RA than the non-rheumatoid synovial tissues [73]. In
another study, using magnetic resonance spectroscopy,
elevated levels of lactate and lower concentration of glu-
cose were shown to be present in the synovial fluid of
RA patients indicating an increased glycolytic activity in
their synovium [74]. Hexokinase (HK3) is an enzyme
that phosphorylates glucose to form glucose-6 phos-
phate. Its activity has been reported to be active in the
synovial fluid of rheumatoid arthritis patients [75,76]. In
our study, HK3 was found to be upregulated by 3.2-fold
in RA. Glucose-6-phosphate isomerase (GPI) catalyzes
the conversion of glucose-6 phosphate in to fructose-6
phosphate in glycolysis pathway. GPI has been impli-
cated as an autoantigen in RA and their levels were
found to be significantly elevated in the serum and syn-
ovial fluid of RA patients than non-RA patients [77,78].
Additionally, elevated serum GPI levels have been re-
ported to be more useful in discriminating RA from
non-RA patients and thereby in the diagnosis of RA
[79]. Autoantibodies to alpha-enolase (ENO1) and al-
dolase A, fructose-bisphosphate (ALDOA) enzymes in-
volved in the glycolytic pathway were also reported in
the sera of RA patients [80,81]. The citrullinated form
of ENO1 has been shown to be more prevalent than itsTable. 3 List of upregulated proteins in RA involved in
glycolytic pathway
Gene symbol Protein Fold change
(RA/OA)
1 HK3 Hexokinase 3 3.2
2 GPI Glucose-6-phosphate isomerase 4.5
3 ALDOA Aldolase A, fructose-bisphosphate 4.5
4 PGK1 Phosphoglycerate kinase 1 4.5
5 PGAM1 Phosphoglycerate mutase 1 7.7
6 ENO1 Enolase 1, (alpha) 4.7
7 PKM2 pyruvate kinase, muscle 3.1
8 LDHA Lactate dehydrogenase A 4.0
9 MDH1 Malate dehydrogenase 1,
NAD (soluble)
3.2native form in the sera of RA patients [82]. In our study,
GPI, ENO1 and ALDOA have been found to be upregulated
by 4.5-fold, 4.7-fold and 4.5-fold respectively. Our quanti-
tative proteomic analysis is in agreement with previous re-
ports and shows a clear association of glycolytic pathway
in RA. In light of this finding, further studies are war-
ranted to investigate this pathway further as a therapeutic
option for RA.
Data availability
The raw data obtained in this study were submitted to
public data repositories, Human Proteinpedia (https://
www.humanproteinpedia.org) and Tranche (https://www.
proteomecommons.org/tranche/). Processed data and the
database search results can be downloaded from Human
Proteinpedia using the following URL, http://www.human-
proteinpedia.org/data_display?exp_id=00702 [83]. The fol-







In this study, we employed an iTRAQ-based approach to
quantitate synovial fluid proteins in RA and OA. A total
of 575 proteins were identified and 135 were found to be
differentially expressed between RA and OA by ≥3-fold.
We identified several proteins that were novel to the study
as well as several described earlier in the context of RA
and OA. We also confirmed the overexpression of CAPG
in RA synovial fluid by MRM as well as by Western blot
analysis. Pathway analysis of upregulated proteins in RA
revealed a significant enrichment of proteins involved in
glycolytic pathway. Further, studies that could unravel the
utility of the differentially expressed proteins which in
turn might aid in early diagnosis, prognosis as well as in
the evaluation of disease progression of RA and OA are
warranted.
Materials and methods
Sample collection and processing
Approximately 2–4 ml of the synovial fluid samples were
aspirated from the affected knees of 10 RA and 10 OA pa-
tients in vacutainers (Becton, Dickinson and Company,
New Jersey, USA) coated with sodium heparin and stored
at 4°C. Only samples collected without any blood contam-
ination during aspiration were included in this study. All
the samples were collected from patients who satisfied the
American College of Rheumatology criteria for RA and
OA [8,84]. The samples were obtained after getting in-
formed consent from the patients and approval from the
ethical committees of the Armed Forces Medical College,
Mitochondrion
Cytosol
Figure 5 Glycolytic pathway enriched from GeneSpring analysis. Proteins upregulated in RA are highlighted in the glycolysis pathway image.
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Command Air Force Hospital, Bangalore, India. Sam-
ples were collected from RA and OA patients with an
average age of 52 and 65 years, respectively. The sam-
ples were centrifuged at 1,500 g at room temperature
for 15 minutes and the supernatants were filtered by
using 0.22 μm filters (Millipore, Ireland). The filtered
samples were stored at -80°C until further analysis.
Depletion of synovial fluid proteome and iTRAQ labeling
Protein estimation of the synovial fluid samples was car-
ried out using Lowry’s method [85]. Five samples each of
OA and RA synovial fluid were pooled separately. The
pooled samples were then depleted to remove the 14 most
abundant proteins (Albumin, haptoglobin, transferrin,
IgA, IgG, alpha 1-antitrypsin, alpha 2-antitrypsin, alpha 1-
acid glycoprotein, apolipoprotein A1, apolipoprotein A2,
complement C3, IgM, transthyretin and fibrinogen) by
using Human 14 multiple affinity removal spin cartridge
(Agilent Technologies, Santa Clara, California, USA). The
depleted protein was then washed and concentrated using
3 kDa MWCO filters (Amicon, Millipore, Ireland). Ap-
proximately 65 μg equivalent of the depleted synovial fluid
protein from each group was subjected to trypsin diges-
tion and iTRAQ labeling as described earlier [21]. Briefly,
denaturation of the protein was done using 2% SDS
followed by reduction and alkylation with reducing agent
tris (2-carboxyethyl) phosphine (TCEP) and cysteine
blocking agent, methyl methanethiosulfonate (MMTS), re-
spectively. Subsequently the samples were digested with
sequencing grade trypsin (Promega, Madison, WI, USA)
at 37°C overnight. The tryptic peptides from each group
were then labeled with 4-plex iTRAQ reagents (iTRAQ
Reagents Multiplex kit, Applied Biosystems, California,
USA) as per the manufacturer’s instructions. OA and RA
synovial fluid derived tryptic peptides were labeled with
116 and 117 iTRAQ labels respectively. The labeled pep-
tides were then pooled, vacuum-dried and reconstituted
in 10 mM KH2PO4, 20% acetonitrile (pH 2.8) (solvent A)
and fractionated by strong cation exchange (SCX)
chromatography.
Strong cation exchange (SCX)-based fractionation
SCX-based fractionation was carried out as described
earlier [20]. In brief, the tryptic peptides were fractionated
on a PolySULFOETHYL A column (PolyLC, Columbia,
MD, USA) with 200 Å, 5 μm, 200 × 2.1 mm dimensions,
using an Agilent’s 1200 HPLC-system (Agilent Technolo-
gies, Santa Clara, California , USA). A linear gradient of
increasing solvent B (350 mM KCl in solvent A, pH 2.8)
at a flow rate of 200 μl/min over a period of 70 min was
used for fractionation. Peptide fractions were collected
using an automated fraction collector. 20 fractions were ob-
tained after fractionation. All the fractions were completelydried and reconstituted in 0.1% trifluoroacetic acid to be
further desalted using stage-tips packed with C18 material
[86]. Desalted fractions were dried in speedvac and recon-
stituted in 10 μl of 0.1% TFA prior to LC-MS/MS analysis.
LC-MS/MS analysis
Tandem mass spectrometric analysis of the iTRAQ la-
beled peptides were carried out using LTQ-Orbitrap Velos
mass spectrometer (Thermo Scientific, Bremen, Germany)
interfaced with Easy nanoLC II (previously Proxeon,
Thermo Scientific, Bremen, Germany). The LC system
consisted of an enrichment column (3 cm× 75 μ) packed
with Magic AQ C18 material, 5 μ particle size with 100 Å
pore size) and an analytical column (10 cm× 75 μ), Magic
AQ C18 material 5 μ particle size, 100 Å pore size) packed
using pressure injection cell at 800 psi. Electrospray
ionization source was fitted with an emitter tip 8 μm
(New Objective, Woburn, MA) and maintained at 2000 V
ion spray voltage. Peptide samples were loaded onto an
enrichment column in 0.1% formic acid, 5% ACN for
15 min and peptide separation carried out using a linear
gradient of 7-35% solvent B (90% ACN in 0.1% formic
acid) for 60 minutes at a constant flow rate of 350 nl/min.
Data was acquired using Xcalibur 2.1 (Thermo Scientific,
Bremen, Germany). The MS spectra were acquired in a
data-dependent manner in the m/z range of 350 to 1800
and survey scans were acquired in Orbitrap mass analyzer
at a mass resolution of 60,000 at 400 m/z. The MS/MS
data was acquired in Orbitrap mass analyzer at a reso-
lution of 15,000 at 400 m/z by targeting top 20 most
abundant ions for fragmentation using higher energy
collisional dissociation activation at 39% normalised
collision energy. Single and unassigned charge state pre-
cursor ions were rejected. The dynamic exclusion op-
tion was enabled during data acquisition with exclusion
duration of 60 seconds. Lock mass option was enabled
for real time calibration using polycyclodimethylsilox-
ane (m/z, 415.12) ions [87].
Data analysis
Proteome Discoverer Beta Version 1.3 (Thermo Fisher
Scientific Inc., Bremen, Germany) was used for database
searches. A precursor mass range of 350–8000 Da and a
signal to noise of 1.5 were used. A combined Mascot
(Mascot version 2.2, Matrix Science) and SEQUEST
search was done using the Proteome Discoverer suite
(Version 1.3.339, Thermo Scientific, Bremen, Germany)
against the NCBI Human RefSeq database 50 containing
33,947 entries with known contaminants. Search param-
eters included trypsin as the enzyme with maximum 1
missed cleavage allowed; oxidation of methionine was
set as a dynamic modification while alkylation at cysteine
and iTRAQ modification at N-terminus of the peptide
and lysine were set as static modifications. Precursor and
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respectively. Peptide and protein data were fetched using
high peptide confidence and rank one peptide match fil-
ters. Reporter ion quantitation node was used for relative
expression pattern of proteins based on the relative inten-
sities of reporter ions for the corresponding peptides. The
raw data obtained was searched against decoy database to
calculate 1% false discovery rate cut-off score [88]. Spectra
that matched to the contaminants and those that did not
pass the 1% FDR threshold were not considered for
analysis.
Multiple reaction monitoring (MRM)
MRM assays [89] were designed to validate the differen-
tially expressed protein, CAPG in RA and OA synovial
fluid. Skyline version 2.1 [90] was used for method devel-
opment and optimization. The target peptide selected for
CAPG was QAALQVAEGFISR (z = +2, m/z = 695.38) and
top four transitions monitored included, y8+→ 878.47,
y7+→ 779.40, y6+→ 708.37 and y5+→ 579.32. The
samples were subjected to in-solution digestion as described
earlier [91]. All samples were analyzed in triplicate on TSQ
Quantum Ultra (Thermo Scientific, San Jose, CA) interfaced
with Easy nanoLC II (previously Proxeon, Thermo Scientific,
Bremen, Germany). The peptides were enriched on a trap
column (5 μm, 75 μm×2 cm.) with 0.1% formic acid and
5% ACN for 5 minutes and separated on an analytical
column (3 μm, 75 μm × 10 cm) with an increasing lin-
ear gradient from 5-35% of solvent B (90% ACN in
0.1% formic acid) for 60 min at a constant flow rate
of 300 nl/min. Both columns were packed in-house
using Magic AQ C18 material (Michrom Bioresources).
Spray voltage of 2.5 kV was applied and ion transfer tube
was maintained at 275°C. The data was acquired with Q1
and Q3 set at resolution of 0.4 and 0.7 respectively. The
collision energy for each transition was optimized with the
help of Skyline based on the preliminary results [90].
Western blot analysis
40 μg of protein from each individual samples of RA (n =
10) and OA (n = 10) synovial fluid was used for Western
blot analysis. The primary antibody used was a rabbit anti-
human polyclonal antibody for CAPG (Proteintech
Group, Inc, Chicago, USA). SDS-PAGE gels were electro-
blotted on nitrocellulose membrane (Whatman Inc.,
Maine, USA) at 250 mA for 2 hours using TE-70 ECL
semi-dry transfer unit (GE Healthcare, Pittsburgh, USA).
The membranes were then blocked with 5% non-fat dry
milk and washed with phosphate buffered saline contain-
ing 0.05% tween (PBST). The membranes were incubated
with primary antibody for 2 hours, washed with PBST and
incubated at room temperature for 1 hour in diluted
(1:2500) anti-rabbit IgG antibody conjugated with horse-
radish peroxidase (GE Healthcare, UK).Bioinformatics analysis
Gene Ontology (GO)-based [92] analysis was done using
Human Protein Reference Database (HPRD) (http://www.
hprd.org), which is a GO compliant database [27,28]. Data
pertaining to sub-cellular localization, biological processes,
domains and motif information associated with the identi-
fied proteins were obtained from HPRD.
GeneSpring Analysis
Pathway Architect module from GeneSpring GX12 was
used to identify significantly enriched pathways. Using
‘single experiment analysis’ tool in the pathway architect
module the differentially expressed list of genes was
searched against publicly available pathways.
Additional file
Additional file 1: Table S1. List of proteins identified from OA and RA
synovial fluid along with the corresponding peptide sequences, coverage,
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117/116 variability, modifications, Xcorr, IonScore, charge, MH+, delta
mass (ppm), retention time (RT).
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